Immunotherapy Safety for the Primary Care ... - U.S. Coast Guard

More documents

Recommendations

Info

Complement-mediated • C5a, C3a, C4a (anaphylotoxins) – plasma – immunoglobulins – dialysis membranes Direct mast cell degranulation
Arachidonic Cascade-mediated • Nonsteroidal anti-inflammatory agents – COX1 – COX2 (?) • Increase in Leukotrienes through blockade of prostaglandin syn<strong>the</strong>sis pathway(s) Direct mast cell degranulation
Page 1 and 2:
Immunotherapy Safety for the Primar
Page 3 and 4:
Welcome to “Immunotherapy Safety
Page 5 and 6:
Click the ⌧ next to the topic to
Page 7 and 8:
Immunotherapy at Remote Sites Stand
Page 9 and 10:
What Immunotherapy Is Not • Not p
Page 11 and 12:
How Does Immunotherapy Work? • De
Page 13 and 14:
Who Benefits? •Those with… - Al
Page 15 and 16:
Immunotherapy Efficacy • Effectiv
Page 17 and 18:
Not Efficacious For… • Atopic d
Page 19 and 20:
The Extracts/Vaccines • Bioequiva
Page 21 and 22:
Lots of Numbers! Vial v/v W/V (exam
Page 23 and 24:
Immunotherapy Phases • Maintenanc
Page 25 and 26:
Reaction Prevention - Avoidance •
Page 27 and 28:
Reaction Therapy - BLS+ Level • T
Page 29 and 30:
Treatment Guidelines • Treatment
Page 31 and 32:
Frequency of Systemic Reactions •
Page 33 and 34:
Immunotherapy Safety • To lessen
Page 35 and 36:
Immunotherapy Safety • To lessen
Page 37 and 38:
Immunotherapy Safety • After Inje
Page 39 and 40:
Immunotherapy Safety • Equipment:
Page 41 and 42:
What To Expect (Demand) from the Al
Page 43 and 44:
Summary • Risk factors for advers
Page 45:
End of Selection Go to Bookmarks &
Page 48 and 49:
• Allergen immunotherapy (allergy
Page 50 and 51:
BEFORE EACH SHOT!!! • Screen pati
Page 52 and 53:
instruct patient to report any abno
Page 54 and 55:
• Negative (swelling up to 15mm;
Page 56 and 57:
Epi-Pen Adult Epi-Pen JR TwinJect
Page 58 and 59:
How to dilute from available vials:
Page 60 and 61:
Vial v/v W/V AU/ML BAU/ML 5 Red 4 G
Page 62 and 63:
Summary • Pull the patient's alle
Page 64 and 65:
Page 66 and 67:
a. Medical conditions that reduce t
Page 68 and 69:
Allergen immunotherapy should be gi
Page 70 and 71:
patient’s peak expiratory flow ra
Page 72 and 73:
7. Neilson L, Johnsen C, Mosbech H,
Page 74 and 75:
Click the ⌧ next to the heading t
Page 76 and 77:
a common practice to alternate the
Page 78 and 79:
ALLERGY IMMUNOTHERAPY (AIT) PROBLEM
Page 80 and 81:
Page 82 and 83:
10. Those patients having their dos
Page 84 and 85:
SPECIFIC INSTRUCTIONS A. PHYSICIAN
Page 86 and 87:
ALLERGY IMMUNOTHERAPY RECORD NNMC,
Page 88 and 89:
Immunotherapy Pre-Injection Questio
Page 90 and 91:
Aeroallergen Dose Adjustment Schedu
Page 92 and 93:
NATIONAL NAVAL MEDICAL CENTER: Alle
Page 94 and 95:
ONGOING COMPETENCY ASSESSMENT OF UN
Page 96 and 97:
Page 98 and 99:
eflecting current robust documentat
Page 100 and 101:
Allergen immunotherapy: A practice
Page 102 and 103:
J ALLERGY CLIN IMMUNOL VOLUME 120,
Page 104 and 105:
Page 106 and 107:
Page 108 and 109:
Page 110 and 111:
Page 112 and 113:
Page 114 and 115:
Page 116 and 117:
Page 118 and 119:
Page 120 and 121:
Page 122 and 123:
Page 124 and 125:
Page 126 and 127:
Page 128 and 129:
Page 130 and 131:
Page 132 and 133:
Page 134 and 135: J ALLERGY CLIN IMMUNOL VOLUME 120,
Page 162 and 163: Immunotherapy Safety for the Primar
Page 164 and 165: 15. A 12 yo male presents for his a
Page 166 and 167: Immunotherapy Safety for the Primar
Page 168 and 169: Site Under Construction
Page 170 and 171: Introduction • “Anaphylaxis”
Page 172 and 173: Revised Nomenclature For Anaphylaxi
Page 174 and 175: Anaphylaxis* Is Not Rare Estimated
Page 176 and 177: Pathophysiology
Page 178 and 179: Pathophysiology
Page 180 and 181: Pathophysiology • Histamine acts
Page 182 and 183: IgE Mediated Reactions • Most Ant
Page 186 and 187: Unknown Mechanisms • Exercise-ind
Page 188 and 189: Anaphylaxis Summary of Signs & Symp
Page 190 and 191: Differential Diagnosis • Pulmonar
Page 192 and 193: Anaphylaxis Grading Scale II • An
Page 194 and 195: Laboratory Studies • IgE antibodi
Page 196 and 197: Guidelines for Treatment • Treatm
Page 198 and 199: Guidelines for Treatment • Treatm
Page 200 and 201: How the Allergist/Immunologist Can
Page 202 and 203: Summary • Anaphylaxis: release of
Page 204 and 205: ANAPHYLAXIS • First reported case
Page 206 and 207: 4) Hymenoptera stings Although almo
Page 208 and 209: • Sulfites are added to all the b
Page 210 and 211: mastocytosis on bone marrow biopsy.
Page 212 and 213: Antihistamines H1 antihistamines (B
Page 214: End of Selection Go to Bookmarks &
Page 224 and 225: The diagnosis and management of ana
Page 234 and 235:
Page 236 and 237:
Page 238 and 239:
Page 240 and 241:
Page 242 and 243:
Page 244 and 245:
Page 246 and 247:
Page 248 and 249:
Page 250 and 251:
Page 252 and 253:
Page 254 and 255:
Page 256 and 257:
Page 258 and 259:
Page 260 and 261:
Page 262 and 263:
Page 264 and 265:
Page 267 and 268:
Page 269 and 270:
c. The patient will be counseled co
Page 271 and 272:
Page 273 and 274:
skin testing typically is performed
Page 275 and 276:
TABLE 3 Required Information on Vac
Page 277 and 278:
TABLE 6 Checklist for Safe Vaccine
Page 279 and 280:
Strength of Recommendations Key cli
Page 281 and 282:
Original articles Evaluation of nea
Page 283 and 284:
Page 285 and 286:
Page 287 and 288:
Page 289 and 290:
Allergy Treatment Record Review Cha
Page 291 and 292:
References Acknowledgment: Linda Co
show all

Immunotherapy Safety for the Primary Care ... - U.S. Coast Guard

Create successful ePaper yourself

Delete template?

Save as template?